Lyra Therapeutics Files Routine 8-K, Confirms Nasdaq Listing

Ticker: LYRA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1327273

Lyra Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyLyra Therapeutics, INC. (LYRA)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: administrative, regulatory-filing, corporate-governance

TL;DR

**LYRA filed a routine 8-K, no major news, just administrative updates.**

AI Summary

Lyra Therapeutics, Inc. filed an 8-K on January 8, 2024, to disclose general corporate information and confirm its registration on The Nasdaq Global Market under the trading symbol LYRA. This filing primarily serves to update administrative details and reiterate its compliance with SEC regulations, rather than announcing a new material event. For investors, this filing is a routine update, indicating no immediate changes to the company's operational or financial status that would significantly impact stock value.

Why It Matters

This filing is a standard administrative update, confirming Lyra Therapeutics' registration and listing on Nasdaq, which is important for maintaining transparency and regulatory compliance.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative and does not contain any information that would introduce new risks or change the company's risk profile.

Analyst Insight

A smart investor would recognize this as a routine administrative filing with no immediate impact on the company's fundamentals or stock price, and thus no specific action is warranted based solely on this 8-K.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of Lyra Therapeutics, Inc.'s 8-K filing dated January 08, 2024?

The 8-K filing by Lyra Therapeutics, Inc. on January 08, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, indicating a routine administrative update rather than a specific material event.

On which stock exchange is Lyra Therapeutics, Inc.'s common stock registered?

Lyra Therapeutics, Inc.'s Common Stock, with a $0.001 par value per share, is registered on The Nasdaq Global Market under the trading symbol LYRA, as stated in the filing.

What is the business address of Lyra Therapeutics, Inc. as listed in the filing?

The business address of Lyra Therapeutics, Inc. is 480 Arsenal Way, Watertown, Massachusetts, 02472, with a business phone number of 617-373-4600.

What is Lyra Therapeutics, Inc.'s Central Index Key (CIK) according to the filing?

Lyra Therapeutics, Inc.'s Central Index Key (CIK) is 0001327273, as specified in the COMPANY DATA section of the filing.

Has Lyra Therapeutics, Inc. undergone any name changes in the past, according to this filing?

Yes, the filing indicates that Lyra Therapeutics, Inc. was formerly known as 480 Biomedical, Inc. (changed on 20120927), Arsenal Vascular, Inc. (changed on 20110826), and Arsenal Medical, Inc. (changed on 20090414).

Filing Stats: 810 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2024-01-08 06:13:25

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Lyra Therapeutics, Inc. (the “Company”) posted a corporate presentation to its website that representatives of the Company may use from time to time in presentations or discussions with investors, analysts or other parties. A copy of the presentation is being furnished as Exhibit 99.1, which is incorporated herein by reference. The information in Item 7.01 of this Current Report on Form 8-K (the “Current Report”) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. The corporate presentation posted to the Company’s website on January 8, 2024 includes data on file as of January 5, 2024 from the BEACON Phase 2 clinical trial, demonstrating statistically significant improvement in loss of smell in a subset of patients with impaired smell at baseline. The data demonstrated a 0.87 improvement over control at week 24 (p=0.026).

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the Company’s additional data on file as of January 5, 2024 from the BEACON Phase 2 clinical trial demonstrating statistically significant improvement in loss of smell in patients with impaired smell at baseline. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the important factors discussed under the caption Risk Factors in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2023 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K. Any such forward-looking statements represent management's estimates as of the date of this Current Report on Form 8-K. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. d) Exhibits Exhibit No. Description 99.1 Corporate Presentation by Lyra Therapeutics, Inc.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: January 8, 2024 By: /s/ Jason Cavalier Jason Cavalier, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing